非创伤性颅内出血住院患者预防性抗癫痫发作药物治疗指南:神经重症监护学会临床实践指南
该指南由神经重症监护学会制定,针对急性非创伤性颅内出血住院成人,围绕三个PICO问题系统评价并Meta分析:是否使用预防性抗癫痫发作药物、选左乙拉西坦还是苯妥英/磷苯妥英、疗程长(>7天)还是短(≤7天)。共15篇文献纳入证据基础,采用GRADE方法形成推荐。结果显示预防性用药未显著改善早期或晚期癫痫发作及死亡率,但不良事件增加、90天功能预后不良的相对风险升高;决策分析提示短疗程可增加质量调整生命年。指南建议避免预防性用药,若使用则选左乙拉西坦并短疗程(≤7天),均为弱推荐、极低质量证据。
要点
- 对无临床或脑电图癫痫发作史的急性非创伤性颅内出血住院成人,建议避免预防性使用抗癫痫发作药物(弱推荐,极低质量证据)。
- 若决定使用抗癫痫发作药物,建议选择左乙拉西坦而非苯妥英/磷苯妥英(弱推荐,极低质量证据)。
- 若使用抗癫痫发作药物,建议短疗程(≤7天)而非长疗程(>7天)(弱推荐,极低质量证据)。
- Meta分析显示预防性用药未显著影响早期或晚期癫痫发作及死亡率,但不良事件增加、90天功能预后不良的相对风险升高。
- 基于一项决策分析,短疗程抗癫痫发作药物预防可增加质量调整生命年。
适用人群与场景
- 急性非创伤性颅内出血住院成人。
- PICO 1关注无临床或脑电图癫痫发作病史的患者。
处置流程与药物剂量
- 建议避免对急性非创伤性颅内出血住院成人预防性使用抗癫痫发作药物(弱推荐,极低质量证据)。
- 若使用抗癫痫发作药物,建议选择左乙拉西坦而非苯妥英/磷苯妥英(弱推荐,极低质量证据)。
- 若使用抗癫痫发作药物,建议短疗程(≤7天)而非长疗程(>7天)(弱推荐,极低质量证据)。
研究设计与关键结果
- 系统评价与Meta分析共纳入15篇文献作为推荐基础。
- PICO 1:预防性使用抗癫痫发作药物对早期癫痫发作(≤14天)、晚期癫痫发作(>14天)或死亡率无显著影响,但Meta分析显示不良事件增加,且90天功能预后不良的相对风险升高。
- PICO 2:与左乙拉西坦相比,苯妥英/磷苯妥英对早期癫痫发作或不良事件未检测到显著正面或负面影响,但点估计倾向于左乙拉西坦。
- PICO 3:基于一项决策分析,短疗程抗癫痫发作药物预防可增加质量调整生命年。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,采用GRADE方法制定推荐。
- 推荐强度与证据质量:避免预防性用药(弱推荐,极低质量证据);若使用优选左乙拉西坦(弱推荐,极低质量证据);短疗程≤7天(弱推荐,极低质量证据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对无临床或脑电图癫痫发作史的急性非创伤性颅内出血住院成人,作者建议避免预防性使用抗癫痫发作药物(弱推荐,极低质量证据)。
- 若临床决定使用抗癫痫发作药物,作者建议选择左乙拉西坦而非苯妥英/磷苯妥英(弱推荐,极低质量证据),并采用短疗程≤7天而非>7天(弱推荐,极低质量证据)。
指南或共识出处
- 指南名称:非创伤性颅内出血住院患者预防性抗癫痫发作药物治疗指南:神经重症监护学会临床实践指南。
- 发布机构:神经重症监护学会(Neurocritical Care Society)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is practice heterogeneity in the use, type, and duration of prophylactic antiseizure medications (ASM) in patients hospitalized with acute nontraumatic intracerebral hemorrhage (ICH).
METHODS: We conducted a systematic review and meta-analysis assessing ASM primary prophylaxis in adults hospitalized with acute nontraumatic ICH. The following population, intervention, comparison, and outcome (PICO) questions were assessed: (1) Should ASM versus no ASM be used in patients with acute ICH with no history of clinical or electrographic seizures? (2) If an ASM is used, should levetiracetam (LEV) or phenytoin/fosphenytoin (PHT/fPHT) be preferentially used? and (3) If an ASM is used, should a long (> 7 days) versus short (≤ 7 days) duration of prophylaxis be used? The main outcomes assessed were early seizure (≤ 14 days), late seizures (> 14 days), adverse events, mortality, and functional and cognitive outcomes. We used Grading of Recommendations Assessment, Development, and Evaluation methodology to generate recommendations.
RESULTS: The initial literature search yielded 1,988 articles, and 15 formed the basis of the recommendations. PICO 1: although there was no significant impact of ASM on the outcomes of early or late seizure or mortality, meta-analyses demonstrated increased adverse events and higher relative risk of poor functional outcomes at 90 days with prophylactic ASM use. PICO 2: we did not detect any significant positive or negative effect of PHT/fPHT compared to LEV for early seizures or adverse events, although point estimates tended to favor LEV. PICO 3: based on one decision analysis, quality-adjusted life-years were increased with a shorter duration of ASM prophylaxis.
CONCLUSIONS: We suggest avoidance of prophylactic ASM in hospitalized adult patients with acute nontraumatic ICH (weak recommendation, very low quality of evidence). If used, we suggest LEV over PHT/fPHT (weak recommendation, very low quality of evidence) for a short duration (≤ 7 days; weak recommendation, very low quality of evidence).
参考来源
- Frontera JA, Rayi A, Tesoro E, et al. Guidelines for Seizure Prophylaxis in Patients Hospitalized with Nontraumatic Intracerebral Hemorrhage: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society. Neurocrit Care. 2024. PMID: 39707127. doi:10.1007/s12028-024-02183-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。